Table 1.
Drugs | classification | Approved Year | Indicated disease | ORR |
---|---|---|---|---|
Azacytidine 20 | DNMT inhibitor | 2004 | MDS | 17.9% |
Vorinostat 32 | HDAC inhibitor | 2006 | CTCL | 30% |
Decitabine 35 | DNMT inhibitor | 2006 | MDS | 42%~54% |
Romidepesin 34 | HDAC inhibitor | 2009 | TCL | 34% |
Ruxolitinib 36 | JAK1/2 inhibitor | 2011 | Myelofibrosis | 30% |
Belinostat 33 | HDAC inhibitor | 2015 | PTCL | 25.8% |
Panobinostat 25 | HDAC inhibitor | 2015 | MM | NA |
MDS, Myelodysplastic syndrome; CTCL, Cutaneous T-cell lymphoma; TCL, T-cell lymphoma; PTCL, Peripheral T-cell lymphoma; MM, Multiple Myeloma, ORR, Objective response rate.